Study guide

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies

Key Takeaways Explain This Topic AI

ISPAD and ADA pediatric guidelines target an individualized HbA1c of <7.0% (<53 mmol/mol) for most children when achievable without severe hypoglycemia, corroborated by CGM metrics: Time in Range (TIR 70–180 mg/dL) >70%, Time Below Range (TBR <70 mg/dL) <4%, Time <54 mg/dL <1%, and glycemic coefficient of variation (%CV) ≤36%.

Total Daily Dose (TDD) of insulin varies dramatically across developmental stages: 0.2–0.5 units/kg/day during the honeymoon phase (partial remission), 0.7–1.0 units/kg/day in prepubertal children, and surging to 1.0–1.5+ units/kg/day during pubertal growth spurts due to growth hormone and sex steroid-mediated physiological insulin resistance.

Basal-bolus regimens divide TDD into 40–50% basal insulin (glargine U-100/U-300, degludec, detemir) and 50–60% rapid-acting prandial insulin (aspart, lispro, glulisine), with prandial doses derived via the Rule of 500 for Insulin-to-Carbohydrate Ratio (ICR = 500 / TDD) and Rule of 1800 for Insulin Sensitivity Factor (ISF = 1800 / TDD).

Advanced insulin delivery technologies—including Continuous Glucose Monitoring (Dexcom G6/G7, FreeStyle Libre 2/3) and Automated Insulin Delivery (AID) hybrid closed-loop systems (Tandem Control-IQ, Insulet Omnipod 5, Medtronic 780G)—significantly improve TIR by 10–15% and minimize nocturnal hypoglycemia via real-time algorithmic basal rate modulation and automated correction boluses.

Mild-to-moderate hypoglycemia is managed via the 'Rule of 15' (15 g fast-acting oral carbohydrates with re-evaluation at 15 minutes; 5–10 g or 0.3 g/kg for toddlers), whereas severe hypoglycemia with seizures or altered responsiveness mandates emergency rescue with weight-stratified glucagon formulations: intranasal Baqsimi 3 mg (for age ≥4 years), SC autoinjectors (Gvoke 0.5 mg if <35 kg or 1 mg if ≥35 kg; Zegalogue 0.6 mg for age ≥6 years), or traditional reconstituted IM/SC glucagon (0.5 mg if <20 kg or 1 mg if ≥20 kg).

Last updated: September 2026

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies

Type 1 Diabetes Mellitus (T1DM) is one of the most common chronic endocrine illnesses of childhood, characterized by autoimmune destruction of insulin-producing pancreatic beta cells in genetically susceptible individuals (frequently associated with HLA-DR3-DQ2 and HLA-DR4-DQ8 haplotypes). The resulting absolute insulin deficiency mandates lifelong exogenous insulin replacement. Managing pediatric T1DM requires clinical specialists to balance tight glycemic control to prevent long-term microvascular and macrovascular complications with the daily realities of erratic eating behaviors, variable physical activity, cognitive development, and the risk of severe neuroglycopenic hypoglycemia.

Glycemic Targets & Continuous Glucose Monitoring (CGM) Metrics

The International Society for Pediatric and Adolescent Diabetes ( ISPAD ) and the American Diabetes Association ( ADA ) recommend an individualized glycemic target HbA1c of < 7.0% (< 53 mmol/mol) for the majority of children, adolescents, and young adults, provided it can be safely attained without significant hypoglycemia or compromised quality of life. In children with frequent hypoglycemia, hypoglycemia unawareness, or limited access to advanced diabetes technology, a less stringent target (e.g., < 7.5%) may be established.

With the universal adoption of Continuous Glucose Monitoring (CGM) in pediatric diabetes care, ambulatory glucose profile (AGP) metrics provide a real-time, dynamic reflection of glycemic stability beyond the retrospective 3-month average provided by HbA1c: ISPAD / ADA Standard Consensus CGM Metrics for Pediatric T1DM:

  • ┌────────────────────────────────────────────────────────┬──────────────────┐
  • │ CGM Metric │ Clinical Target │
  • ├────────────────────────────────────────────────────────┼──────────────────┤
  • │ Time in Range (TIR: 70–180 mg/dL [3.9–10.0 mmol/L]) │ > 70% of readings│
  • │ Time Below Range (TBR Level 1: 54–69 mg/dL) │ < 4% of readings │
  • │ Time Below Range (TBR Level 2: < 54 mg/dL) │ < 1% of readings │
  • │ Time Above Range (TAR Level 1: 181–250 mg/dL) │ < 25% of readings│
  • │ Time Above Range (TAR Level 2: > 250 mg/dL) │ < 5% of readings │
  • │ Glycemic Variability (Coefficient of Variation [%CV]) │ ≤ 36% (stable) │
  • └────────────────────────────────────────────────────────┴──────────────────┘

Each 10% increase in TIR (approximately 2.4 hours per day) correlates with an approximate 0.5% to 0.8% reduction in HbA1c and a meaningful risk reduction for pediatric retinopathy, microalbuminuria, and neuropathy.

Total Daily Dose (TDD) Across Pediatric Developmental Stages

Insulin replacement therapy must mirror endogenous pancreatic physiology while adjusting for developmental changes in somatic growth, insulin receptor sensitivity, and neuroendocrine surges: Developmental Progression of Total Daily Insulin Dosing (TDD):

0.2 - 0.5 units/kg/day 0.7 - 1.0 units/kg/day 1.0 - 1.5+ units/kg/day 0.7 - 1.0 units/kg/day

┌─────────────────────────┐ ┌─────────────────────────┐ ┌─────────────────────────┐ ┌─────────────────────────┐

  • │ HONEYMOON PHASE │ │ PREPUBERTAL CHILD │ │ PUBERTAL GROWTH SPURT │ │ POST-PUBERTAL │
  • │ │ │ │ │ │ │ │
  • │ • Partial beta remission│ │ • Steady somatic growth │ │ • GH & sex steroid peak │ │ • Near adult biology │
  • │ • Residual C-peptide │ │ • High insulin sensitiv.│ │ • Severe physiologic IR │ │ • Normalized sensitivity│
  • │ • Low hypoglycemia risk │ │ • Dilute/half-unit pens │ │ • Escalating meal doses │ │ • Weight-based stable │

└─────────────────────────┘ └─────────────────────────┘ └─────────────────────────┘ └─────────────────────────┘

1. The Honeymoon Phase (Partial Remission)

Timing & Biology: Occurs within weeks to months following initial diagnosis and metabolic stabilization after DKA or severe hyperglycemia. Driven by temporary recovery of surviving pancreatic beta cells following relief of glucotoxicity and lipotoxicity.

Insulin Requirements: 0.2 to 0.5 units/kg/day .

Clinical Practice Pearl: Exogenous insulin therapy should never be completely discontinued , even if blood glucose values remain near normal. Maintaining low-dose exogenous insulin (e.g., 0.1–0.2 units/kg/day basal) preserves residual beta-cell mass, sustains endogenous C-peptide secretion, reduces glycemic variability, and prolongs the duration of the partial remission phase.

2. Prepubertal Children

Age & Physiology: Toddlers and school-age children (approx. ages 1 to 10 years).

Insulin Requirements: 0.7 to 1.0 units/kg/day .

Clinical Nuances: Young children possess high insulin sensitivity and low glycogen stores, putting them at elevated risk for rapid hypoglycemia. Small variations in dietary intake (e.g., refusal to finish a meal) or physical activity (unplanned playground running) precipitate acute hypoglycemia. Half-unit insulin pens or diluted insulins (e.g., U-10 regular or lispro prepared by specialized compounding pharmacies) may be necessary for infants and toddlers.

3. Pubertal Growth Spurt

Age & Physiology: Tanner stages 2 through 4 (typically ages 10 to 14 in females, 12 to 16 in males).

Insulin Requirements: Surges to 1.0 to 1.5+ units/kg/day (occasionally reaching 1.8–2.0 units/kg/day).

Mechanistic Basis: Markedly elevated nocturnal pulsatile secretion of growth hormone (GH) and surges in sex steroids (estrogen and testosterone) induce profound hepatic and peripheral insulin resistance by dampening insulin receptor substrate-1 (IRS-1) signaling and down-regulating GLUT4 glucose transporter translocation.

4. Post-Pubertal Stabilization

Requirements: TDD gradually recedes to 0.7 to 1.0 units/kg/day as growth plates fuse, growth hormone secretion declines, and adult body composition stabilizes.

Basal-Bolus Pharmacotherapy

Physiologic multi-dose injection (MDI) regimens partition the TDD into two distinct components:

Basal Insulin (40% to 50% of TDD): Suppresses hepatic gluconeogenesis and lipolysis during the fasting state (overnight and between meals).

Prandial Rapid-Acting Bolus Insulin (50% to 60% of TDD): Disposed across meals and snacks to match carbohydrate absorption and correct inter-current hyperglycemia.

Insulin Class & Agent Onset of Action Peak Effect Duration of Action Pediatric Considerations & Dosing Pearls

Glargine U-100 ( Lantus, Basaglar ) 1.5–2 hours Flat (peakless) 20–24 hours Approved ≥6 years (Lantus). Acidic pH (4.0) causes burning on injection. Usually given once daily at bedtime.

Glargine U-300 ( Toujeo ) 6 hours Flat / Peakless 30–36 hours Approved ≥6 years. Smaller depot surface area yields slower, more constant release than U-100; reduces nocturnal hypoglycemia.

Degludec U-100/U-200 ( Tresiba ) 1 hour Flat / Peakless > 42 hours Approved ≥1 year. Soluble dihexamers form multihexamer chains in SC depot; half-life ~25 hours. Lowest rate of nocturnal hypoglycemia; permits flexible injection timing.

Detemir ( Levemir ) 1–2 hours 6–8 hours 12–20 hours Approved ≥2 years. Hydrophobic myristic acid side-chain binds reversibly to albumin. Shorter duration in pediatrics; often requires BID dosing.

Aspart / Lispro / Glulisine 10–15 minutes 1–2 hours 3–5 hours Standard rapid-acting analogs. Aspart approved ≥2 yr, Lispro approved ≥3 yr, Glulisine approved ≥4 yr. Preferred prandial agents.

Faster Aspart (Fiasp) / Lispro-aabc (Lyumjev) 2–5 minutes 30–60 minutes 2.5–3 hours Fiasp contains niacinamide (speeds absorption); Lyumjev contains treprostinil (local vasodilation). May be given at meal start.

Bolus Timing Considerations in Pediatrics

Standard Timing: Rapid-acting analogs should ideally be administered 10 to 15 minutes before the meal . This allows insulin absorption kinetics to coincide precisely with postprandial glucose absorption from the gastrointestinal tract, preventing early glycemic spikes and late postprandial hypoglycemia.

The Toddler / Picky Eater Exception: In toddlers, infants, or children with unpredictable meal consumption, pre-meal bolusing carries severe risk if the child subsequently refuses to eat. In these specific patients, prandial insulin should be administered immediately after the meal (within 20 minutes of meal initiation) , dosing strictly for the carbohydrates actually ingested.

Carbohydrate Counting & Clinical Dosing Formulas

Prandial dosing requires two distinct calculations: the Carbohydrate Coverage Bolus and the Correction Bolus . Core Pediatric Insulin Dosing Mathematical Formulas:

1. Total Daily Dose (TDD):

TDD (units/day) = Weight (kg) × Developmental Factor (units/kg/day)

2. Basal Component (40-50%): Prandial Component (50-60%):

Basal = TDD × 0.40 to 0.50 Prandial = TDD × 0.50 to 0.60 (divided among meals)

3. Insulin-to-Carbohydrate Ratio (ICR) - Rule of 500:

ICR (grams carb covered by 1 unit) = 500 / TDD

4. Insulin Sensitivity Factor (ISF / Correction) - Rule of 1800 (Rapid-Acting):

ISF (mg/dL drop produced by 1 unit) = 1800 / TDD

5. Total Meal Bolus Calculation:

  • Total Bolus = Carb Bolus + Correction Bolus
  • Total Bolus = (Carbohydrate Intake [g] / ICR) + ([Current BG - Target BG] / ISF)
  • Step-by-Step Clinical Calculation Example

Patient: A 12-year-old adolescent weighing 50 kg presenting in active puberty (Tanner 3). The clinician selects a TDD of 1.2 units/kg/day .

Step 1: Calculate TDD: TDD = 50 kg × 1.2 units/kg/day = 60 units/day \text{TDD} = 50 \text{ kg} \times 1.2 \text{ units/kg/day} = 60 \text{ units/day} TDD = 50 kg × 1.2 units/kg/day = 60 units/day

Step 2: Partition Basal and Prandial:

Basal (40%): 60 × 0.40 = 24 units 60 \times 0.40 = 24 \text{ units} 60 × 0.40 = 24 units of insulin degludec once daily.

Prandial (60%): 60 × 0.60 = 36 units 60 \times 0.60 = 36 \text{ units} 60 × 0.60 = 36 units rapid-acting insulin divided among meals (~12 units/meal).

Step 3: Calculate ICR (Rule of 500): ICR = 500 60 ≈ 8.33 → 1 unit covers 8 grams of carbohydrate \text{ICR} = \frac{500}{60} \approx 8.33 \rightarrow 1 \text{ unit covers } 8 \text{ grams of carbohydrate} ICR = 60 500 ​ ≈ 8.33 → 1 unit covers 8 grams of carbohydrate

Step 4: Calculate ISF (Rule of 1800): ISF = 1800 60 = 30 mg/dL per unit of rapid-acting insulin \text{ISF} = \frac{1800}{60} = 30 \text{ mg/dL per unit of rapid-acting insulin} ISF = 60 1800 ​ = 30 mg/dL per unit of rapid-acting insulin

Step 5: Solve a Mealtime Bolus:

The patient consumes a meal with 64 grams of carbohydrates .

Bedside glucose is 220 mg/dL (Target blood glucose: 100 mg/dL ).

Carb Bolus: 64 g 8 g/unit = 8.0 units \frac{64 \text{ g}}{8 \text{ g/unit}} = 8.0 \text{ units} 8 g/unit 64 g ​ = 8.0 units

Correction Bolus: 220 − 100 30 = 120 30 = 4.0 units \frac{220 - 100}{30} = \frac{120}{30} = 4.0 \text{ units} 30 220 − 100 ​ = 30 120 ​ = 4.0 units

Total Rapid-Acting Bolus: 8.0 + 4.0 = 12.0 units 8.0 + 4.0 = \mathbf{12.0 \text{ units}} 8.0 + 4.0 = 12.0 units

Active Insulin Time (Insulin on Board - IOB): The physiological duration of action of rapid-acting analogs is 3 to 4 hours . Correction doses must account for residual active insulin to prevent insulin stacking , a major cause of late postprandial hypoglycemia.

Advanced Insulin Delivery Technologies Architecture of an Automated Insulin Delivery (AID) / Hybrid Closed-Loop System:

  • ┌─────────────────────────┐ Bluetooth ┌─────────────────────────┐
  • │ Continuous Glucose │ ──────────────────────────────► │ Algorithmic Controller │
  • │ Monitor (CGM) Sensor │ Transmits glucose │ (In Pump or Smartphone) │
  • │ (Subcutaneous interstitial every 5 minutes │ │
  • │ glucose measurement) │ │ • MPC / PID Algorithm │
  • └─────────────────────────┘ │ • Predicts BG in 30 min │
  • │ • Modulates basal rate │
  • │ • Auto-correction bolus │
  • └───────────┬─────────────┘
  • │
  • │ Commands delivery
  • ▼
  • ┌─────────────────────────┐
  • │ Continuous Subcutaneous │
  • │ Insulin Pump (CSII) │
  • │ (Tubed or Tubeless Pod) │
  • └─────────────────────────┘
  • 1. Continuous Glucose Monitoring (CGM)

Mechanisms: Disposable subcutaneous sensor measuring glucose concentration in interstitial fluid via glucose oxidase-catalyzed electrochemical oxidation. A physiological lag time of 5 to 10 minutes exists between interstitial glucose and capillary blood glucose (more pronounced during rapid glucose shifts).

Primary Systems:

Dexcom G6 / G7: Factory-calibrated (no fingersticks needed for treatment decisions). 10-day (G6) or 10.5-day (G7) wear. Features customizable alarms including an Urgent Low 55 mg/dL alarm that cannot be silenced, and predictive alerts (alarms if predicted <55 mg/dL within 20 minutes).

Abbott FreeStyle Libre 2 / 3: Factory-calibrated, 14-day wear. Ultra-miniaturized continuous streaming glucose with customizable threshold alarms.

Mean Absolute Relative Difference (MARD): Contemporary CGM systems achieve a MARD of < 9% , demonstrating clinical parity with fingerstick blood glucose meters.

2. Continuous Subcutaneous Insulin Infusion (CSII - Pumps)

Tubed Pumps (e.g., Tandem t:slim X2, Medtronic 780G): Infuse rapid-acting insulin through external tubing connecting to a subcutaneous cannula. Allows basal rates programmable down to 0.001–0.05 units/hr, ideal for insulin-sensitive infants.

Tubeless Patch Pumps (e.g., Insulet Omnipod 5, Omnipod DASH): Direct-adhesion waterproof "pod" containing insulin reservoir and automated internal cannula inserter, controlled via a wireless handheld personal diabetes manager (PDM) or smartphone app. Highly popular in pediatrics due to absence of snagging tubing.

Cannula Considerations: Teflon soft cannulas vs. 90-degree or angled stainless steel needles (indicated for children with repeated cannula kinking, lean body habitus, or lipodystrophy). Cannulas must be rotated every 48 to 72 hours to prevent lipohypertrophy, erratic absorption, and infusion site abscesses.

3. Automated Insulin Delivery (AID) / Hybrid Closed-Loop Systems

Tandem Control-IQ (pairs with Dexcom G6/G7): Predicts glucose 30 minutes in advance using a Proportional-Integral-Derivative (PID) algorithm. Automatically increases basal rates if BG >160 mg/dL, delivers an automated correction bolus (up to 1 bolus per hour) if BG is predicted >180 mg/dL, decreases basal delivery if BG <112.5 mg/dL, and suspends insulin if BG is predicted <70 mg/dL. Includes specialized Sleep Activity Mode (targets 112.5–120 mg/dL without auto-boluses) and Exercise Activity Mode (targets 140–160 mg/dL to prevent exertion hypoglycemia).

Insulet Omnipod 5 (pairs with Dexcom G6/G7 or FreeStyle Libre 2 Plus): Tubeless system utilizing an embedded Model Predictive Control (MPC) algorithm that updates basal delivery every 5 minutes based on predicted glucose 60 minutes out. Allows customizable target glucose setpoints from 110 to 150 mg/dL in 10 mg/dL increments.

Medtronic MiniMed 780G (with Guardian 4): Delivers automated basal adjustments and auto-corrections every 5 minutes, targeting setpoints as low as 100 mg/dL .

Clinical Impact: AID systems consistently elevate pediatric TIR by 10% to 15% (translating to ~2.5 to 3.5 more hours per day in range), virtually eliminate nocturnal hypoglycemia, and reduce caregiver nocturnal monitoring burden.

Hypoglycemia Management & Emergency Glucagon Formulations Hypoglycemia Severity Classification & Pediatric Treatment Protocol:

LEVEL 1: Mild (54 - 69 mg/dL) LEVEL 2: Significant (< 54 mg/dL) LEVEL 3: Severe (Cognitive Loss / Seizure)

┌──────────────────────────────────────┐ ┌──────────────────────────────────────┐ ┌──────────────────────────────────────┐

│ • Tremor, tachycardia, hunger │ │ • Neuroglycopenia, confusion, ataxia │ │ • Unconscious, seizing, uncooperative│

  • │ • Patient alert and oriented │ │ • Patient retains swallow reflex │ │ • High risk of pulmonary aspiration │
  • │ │ │ │ │ │
  • │ Rx: "RULE OF 15" │ │ Rx: "RULE OF 15" (Fast Carbohydrate) │ │ Rx: EMERGENCY GLUCAGON RESCUE │

│ • 15 g simple oral fast-acting carb │ │ • 15-20 g simple fast-acting carb │ │ • Baqsimi 3 mg intranasal (≥4 yr) │

│ (Toddlers: 5-10 g or 0.3 g/kg) │ │ • Re-check blood glucose in 15 min │ │ • Gvoke SC autoinjector (<35 kg:0.5mg)│

│ • Re-check BG in 15 minutes │ │ • Repeat if still < 70 mg/dL │ │ • Zegalogue 0.6 mg SC (≥6 yr) │

│ • Repeat if still < 70 mg/dL │ │ • Follow with complex carb + protein │ │ • Lateral recovery position (emesis) │

└──────────────────────────────────────┘ └──────────────────────────────────────┘ └──────────────────────────────────────┘

The Rule of 15 for Conscious Patients

Administer 15 grams of fast-acting simple carbohydrates (e.g., 4 ounces [1/2 cup] of fruit juice or regular soda, 3 to 4 chewable glucose tablets, or 1 tube of glucose gel).

Toddler Modification: In infants and young children (<5 years or <20 kg), 15 grams may cause marked rebound hyperglycemia; administer 5 to 10 grams of carbohydrate (or 0.3 g/kg ).

Wait 15 minutes and retest capillary blood glucose. If glucose remains < 70 mg/dL , repeat with an additional 15 grams of fast-acting carbohydrate.

Once blood glucose normalizes (≥70 mg/dL), if the next scheduled meal is more than 1 hour away, provide a snack containing complex carbohydrates and protein (e.g., peanut butter crackers, cheese and bread) to maintain euglycemia.

Emergency Rescue Formulations for Severe Hypoglycemia

Severe hypoglycemia (Level 3) is a life-threatening pediatric emergency characterized by severe cognitive impairment, loss of consciousness, or generalized convulsions. Oral carbohydrates are strictly contraindicated due to imminent risk of pulmonary aspiration.

Glucagon Formulation Delivery Route & Formulation Pediatric Age & Weight Dosing Clinical Instructions & Storage Pearls

Baqsimi Intranasal Powder (Single-use device) 3 mg for children ≥ 4 years of age (same dose for all ages/weights ≥4 yr) Needle-free dry powder absorbed passively across nasal mucosa; effective even with severe nasal congestion, rhinitis, or common cold. Keep shrink-wrapped until use; store up to 30°C (86°F).

Gvoke ( HypoPen / Prefilled Syringe ) Subcutaneous Solution (Pre-mixed, room-temp liquid) < 35 kg (or age 2–11 yr): 0.5 mg SC ; ≥ 35 kg (or age ≥12 yr): 1.0 mg SC Room-temperature liquid in pre-filled autoinjector. Push firmly against outer thigh until click is heard; hold for 5 seconds. Approved ≥2 years.

Zegalogue ( Dasiglucagon ) Subcutaneous Solution (Synthetic peptide analog) 0.6 mg SC for patients ≥ 6 years of age Novel glucagon receptor peptide agonist stable in aqueous solution. Pre-filled syringe or autoinjector. Median time to glucose recovery is 10 minutes.

Reconstituted Glucagon Emergency Kit (GEK) IM / SC Injection (Dry powder + diluent syringe) < 20 kg (or age <6 yr): 0.5 mg ; ≥ 20 kg (or age ≥6 yr): 1.0 mg High failure and delay rate in emergencies due to parental panic during multi-step reconstitution. Rotate reconstituting syringe, inject into vastus lateralis.